In patients, long‐acting GLP‐1R analogues such as liraglutide and semaglutide have been used for treatment of type 2 diabetes mellitus (T2DM), and obesity and are known to decrease cardiovascular disease and chronic kidney disease in people with T2DM.2, 3, 4, 5. Here, GLP1R is linked to chronic kidney disease.